A novel dosage approach for evaluation of SMANCS [poly-(styrene-co-maleyl-half-n-butylate) - neocarzinostatin] in the treatment of primary hepatocellular carcinoma.
We report a Phase I/II clinical trial of poly-(styrene-co-maleyl-half-n-butylate)-neocarzinostatin (SMANCS) for intra-arterial treatment of hepatoma. Early patients received 4 or 8 mg SMANCS dissolved in Lipiodol; later patients were treated according to tumour size and degree of filling achieved. SMANCS/Lipiodol drained rapidly from normal liver but was retained within tumour interstitium. Tumour nodules filled with SMANCS/Lipiodol usually stabilised and often regressed. No UICC criteria-defined responses were achieved, partly due to difficulties of filling several lesions simultaneously. Signs of therapeutic activity suggest a more extensive clinical study is warranted.
Seymour
L W
LW
CRC Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Olliff
S P
SP
Poole
C J
CJ
De Takats
P G
PG
Orme
R
R
Ferry
D R
DR
Maeda
H
H
Konno
T
T
Kerr
D J
DJ
D015746:Abdominal Pain / Q000139:chemically induced; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000188:drug therapy*; D004341:Drug Evaluation; D004342:Drug Hypersensitivity / Q000209:etiology; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D007269:Injections, Intra-Arterial; D008099:Liver / Q000000981:diagnostic imaging / Q000473:pathology; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008297:Male; D008299:Maleic Anhydrides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D011137:Polystyrenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011859:Radiography; D013575:Syncope / Q000139:chemically induced; D016896:Treatment Outcome; D009353:Zinostatin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000509:alpha-Fetoproteins / Q000032:analysis / Q000378:metabolism
D000970:Antineoplastic Agents; D008299:Maleic Anhydrides; D011137:Polystyrenes; D000509:alpha-Fetoproteins; C035755:poly(maleic acid-styrene)neocarzinostatin; D009353:Zinostatin